MARINUS PHARMACEUTICALS, INC. - COMMON STOCK (MRNS)

CUSIP: 56854Q200

Q1 2023 13F Holders as of 31 Mar 2023

Holder snapshot 7 signals
Share change
+2,295,900
Put/Call ratio
11%
SEC-reported price per share
$6.90
Indexed holders
85
Value change
+$27,882,072
Number of buys
57
Open additional details 1 more signal available
Number of sells
35
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
54,731,500

Security key

56854Q200

Report period

Q1 2023

Indexed institutions

85

Top holders

10

Ownership snapshot

Top reported holders of MRNS - MARINUS PHARMACEUTICALS, INC. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Lion Point Capital, LP
Disclosed value leader
Lion Point Capital, LP
Comparable rows
0/15
Latest evidence
31 Dec 2022
13F Highest disclosed value: $21,480,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Lion Point Capital, LP has the largest disclosed position value at $21.48M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Lion Point Capital, LP's linked filing trail.
Disclosed position value Top 5
Lion Point Capital, LP $21.48M
MONTANOVA CAPITAL, LLC $19.2M
Point72 Asset Management, L.P. $13.99M
Avoro Capital Advisors LLC $12.54M
EVENTIDE ASSET MANAGEMENT, LLC $12.54M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Lion Point Capital, LP
13F
Company
13F
—
denominator unverified
$21,480,000
4,222,648 shares
— 31 Dec 2022
MONTANOVA CAPITAL, LLC
13F
Company
13F
—
denominator unverified
$19,195,520
4,822,995 shares
— 31 Dec 2022
Point72 Asset Management, L.P.
13F
Company
13F
—
denominator unverified
$13,989,700
3,515,000 shares
— 31 Dec 2022
Avoro Capital Advisors LLC
13F
Company
13F
—
denominator unverified
$12,537,000
3,150,000 shares
— 31 Dec 2022
EVENTIDE ASSET MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$12,537,000
3,150,000 shares
— 31 Dec 2022
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F
Company
13F
—
denominator unverified
$8,168,950
2,052,500 shares
— 31 Dec 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
85
Shares
41,133,046
Indexed holders
85
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2023 vs Q4 2022 Across Filers

Q4 2022 indexed holders
71
Q1 2023 indexed holders
85
Indexed holder difference
14
Investor Q4 2022 Shares Q1 2023 Shares Share Diff Share Chg % Q4 2022 value Q1 2023 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .